Abstract:Aims The activation of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in endothelial cells (ECs) contributes to vascular inflammation in atherosclerosis. Considering the high glycolytic rate of ECs, we delineated whether and how glycolysis determines endothelial NLRP3 inflammasome activation in atherosclerosis.Methods and results Our results demonstrated a significant up-regulation of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a key regulator of glycolysis, in human and mouse atherosclerotic endothelium, which positively correlated with NLRP3 levels. Atherosclerotic stimuli up-regulated endothelial PFKFB3 expression via sterol regulatory element-binding protein 2 (SREBP2) transactivation. EC-selective haplodeficiency of Pfkfb3 in Apoe-/- mice resulted in reduced endothelial NLRP3 inflammasome activation and attenuation of atherogenesis. Mechanistic investigations revealed that PFKFB3-driven glycolysis increased the NADH content and induced oligomerization of C-terminal binding protein 1 (CtBP1), an NADH-sensitive transcriptional co-repressor. The monomer form, but not the oligomer form, of CtBP1 was found to associate with the transcriptional repressor Forkhead box P1 (FOXP1) and acted as a transrepressor of inflammasome components, including NLRP3, caspase-1, and interleukin-1 beta (IL-1 beta). Interfering with NADH-induced CtBP1 oligomerization restored its binding to FOXP1 and inhibited the glycolysis-dependent up-regulation of NLRP3, Caspase-1, and IL-1 beta. Additionally, EC-specific overexpression of NADH-insensitive CtBP1 alleviates atherosclerosis.Conclusion Our findings highlight the existence of a glycolysis-dependent NADH/CtBP/FOXP1-transrepression pathway that regulates endothelial NLRP3 inflammasome activation in atherogenesis. This pathway represents a potential target for selective PFKFB3 inhibitors or strategies aimed at disrupting CtBP1 oligomerization to modulate atherosclerosis. Graphical Abstract

Cbl Negatively Regulates NLRP3 Inflammasome Activation through GLUT1-Dependent Glycolysis Inhibition

SLC25A3 Negatively Regulates NLRP3 Inflammasome Activation by Restricting the Function of NLRP3

Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation

CCDC50 Suppresses NLRP3 Inflammasome Activity by Mediating Autophagic Degradation of NLRP3

The Pathogenic Role of NLRP3 Inflammasome Activation in Inflammatory Bowel Diseases of Both Mice and Humans.

The Inhibitor Effect of RKIP on Inflammasome Activation and Inflammasome-Dependent Diseases

Endothelial Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3 Inflammasome Regulation in Atherosclerosis.

The Angiotensin II Receptor Neprilysin Inhibitor LCZ696 Inhibits the NLRP3 Inflammasome By Reducing Mitochondrial Dysfunction in Macrophages and Alleviates Dextran Sulfate Sodium-induced Colitis in a Mouse Model

Hematopoietic Cell Kinase (HCK) Is Essential for NLRP3 Inflammasome Activation and Lipopolysaccharide-Induced Inflammatory Response In Vivo

The regulation of NLRP3 inflammasome activation by CCDC50-mediated autophagy

Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming

The Glycolytic Metabolite Methylglyoxal Covalently Inactivates the NLRP3 Inflammasome

NF-κB Downregulates Cbl-b Through Binding and Suppressing Cbl-b Promoter in T Cell Activation.

E3 Ligase C-Cbl Regulates Intestinal Inflammation Through Suppressing Fungi-Induced Noncanonical NF-κΒ Activation

Chloride sensing by WNK1 regulates NLRP3 inflammasome activation and pyroptosis

The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer

Endothelial NLRP3 inflammasome regulation in atherosclerosis

Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia

NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis

GSNOR negatively regulates the NLRP3 inflammasome via S -nitrosation of MAPK14

Cystathionine β-Synthase Suppresses NLRP3 Inflammasome Activation via Redox Regulation in Microglia.